Rabbani, S.A.; Saini, M.; El-Tanani, M.; Kumar, R.; Matalka, I.; El-Tanani, Y.; Sharma, S.; Rizzo, M.
Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. Pharmaceuticals 2026, 19, 732.
https://doi.org/10.3390/ph19050732
AMA Style
Rabbani SA, Saini M, El-Tanani M, Kumar R, Matalka I, El-Tanani Y, Sharma S, Rizzo M.
Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. Pharmaceuticals. 2026; 19(5):732.
https://doi.org/10.3390/ph19050732
Chicago/Turabian Style
Rabbani, Syed Arman, Manita Saini, Mohamed El-Tanani, Rakesh Kumar, Ismail Matalka, Yahia El-Tanani, Shrestha Sharma, and Manfredi Rizzo.
2026. "Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies" Pharmaceuticals 19, no. 5: 732.
https://doi.org/10.3390/ph19050732
APA Style
Rabbani, S. A., Saini, M., El-Tanani, M., Kumar, R., Matalka, I., El-Tanani, Y., Sharma, S., & Rizzo, M.
(2026). Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. Pharmaceuticals, 19(5), 732.
https://doi.org/10.3390/ph19050732
